Background: Data on the burden of genital warts in terms of treatment costs and detriment to
quality of life (QoL) are required to assess cost-effectiveness of quadrivalent human …

Objectives To estimate the loss of quality of life and cost of treatment associated with genital
warts seen in sexual health clinics. Methods A cross-sectional questionnaire study and case …

The national cost of managing genital warts (GWs) in the UK has not been fully estimated,
yet is required to inform decisions on vaccination against human papillomavirus. This study …

Objective The quadrivalent human papillomavirus (HPV) vaccine is effective against HPV
types responsible for 90% of anogenital warts. This study estimated the quality of life lost to …

OBJECTIVE: Worldwide, genital warts, caused by human papillomavirus (HPV) is a
common, sexually transmitted disease. The overall disease management strategy for genital …

Background Human papillomavirus (HPV) is a necessary cause of cervical cancer. HPV is
also responsible for benign condylomata acuminata, also known as genital warts. We …

Objectives: To determine the average cost of a case of genital warts, for both males and
females, with a view to informing the current debate as to which Human papillomavirus …

Genital warts, 90% of which are caused by human papillomavirus types 6 and 11, are a
significant problem in the UK. The cost of managing genital warts was previously estimated …

Abstract Background In Italy the prevalence of genital warts in women (15–64 years) is
approximately 0.6% with an incidence of 0.4% per year. Treatments for GW are usually long …

External genital warts (EGW) are a sexually transmitted infection caused by various strains
of human papillomavirus (HPV). Several studies have described the direct and indirect costs …